Champions Oncology (NASDAQ:CSBR) shares were 11% higher in Friday’s pre-market session after the company reported a fiscal Q1 adjusted net loss of $0.15 per share, which came in narrower than the $0.24 loss per share in the prior year period Total revenues for the quarter ended July 31 were $3.7 million, up from $2.8 million reported for the same period last year. The company expects full year 2017 revenues to range from $16 million to $18 million. Analyst estimates were not available for comparison.
The stock decreased 1.18% or $0.02 on September 13, hitting $1.67. About 59,499 shares traded hands. Champions Oncology Inc (NASDAQ:CSBR) has declined 54.57% since February 8, 2016 and is downtrending. It has underperformed by 71.06% the S&P500.
Champions Oncology, Inc. is engaged in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. The company has a market cap of $17.59 million. The Firm has two business divisions: Personalized Oncology Solutions and Translational Oncology Solutions (TOS). It currently has negative earnings. The POS segment provides physicians and patients information to help guide the development of personalized treatment plans.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.